BRIEF-PepGen Reports Positive Data From Phase 1 Trial Of PGN-EDO51 For Treatment Of Duchenne Muscular Dystrophy

Reuters
28 Sep 2022

Sept 28 (Reuters) - PepGen Inc :

* PEPGEN REPORTS POSITIVE DATA FROM PHASE 1 TRIAL OF PGN-EDO51 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

* PEPGEN INC - PGN-EDO51 WAS GENERALLY WELL-TOLERATED

* PEPGEN INC - PEPGEN PLANS TO INITIATE A PHASE 2A MULTIPLE ASCENDING DOSE $(MAD.AU)$ CLINICAL TRIAL IN DUCHENNE MUSCULAR DYSTROPHY $(DMD)$ PATIENTS IN 1H 2023

* PEPGEN INC - DATA SUPPORTS POTENTIAL OF PEPGEN'S ENHANCED DELIVERY OLIGONUCLEOTIDE (EDO) PLATFORM IN NEUROMUSCULAR DISEASES

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10